Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of ASP2408 in Healthy Males
NCT02140125Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2012
- Primary completion
- Oct 2013
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP2408 in rheumatoid arthritis (RA) (4 arms), sponsored by Astellas Pharma. Primary endpoint: Safety assessed by the incidence of adverse events, vital signs, lab tests, and 12-lead ECG. Started Aug 2012; status: completed.
02
Drugs
ASP2408
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02140125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140125.